Treatment of arginase deficiency revisited: Guanidinoacetate as a therapeutic target and biomarker for therapeutic monitoring

Developmental Medicine and Child Neurology

Volumn 56, Issue 10, 2014, Pages 1021-1024

  Amayreh, Wajdi ^a   Meyer, Uta ^a   Das, Anibh M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER; CREATINE; GLYCINE; GUANIDINOACETIC ACID; ORNITHINE;

ANALOGS AND DERIVATIVES; BLOOD; CASE REPORT; CHILD; DIET THERAPY; HUMAN; HYPERARGININEMIA; MALE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

BENZOATES; BIOLOGICAL MARKERS; CHILD; CREATINE; GLYCINE; HUMANS; HYPERARGININEMIA; MALE; ORNITHINE; TREATMENT OUTCOME;

EID: 84908390761     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.12488     Document Type: Article

References (15)

1. Sparkes RS, Dizikes GJ, Klisak I, et al. The gene for human arginase (ARG1) is assigned to chromosome band 6q23. Am J Hum Genet 1986; 39: 186-93.
2. Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab 2005; 84: 243-51.
3. Scaglia F, Lee B. Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency. Am J Med Genet C Semin Med Genet 2006; 142C: 113-20.
4. Carvalho DR, Brum JM, Speck-Martins CE, et al. Clinical features and neurologic progression of hyperargininemia. Pediatr Neurol 2012; 46: 369-74.
5. Braga AC, Vilarinho L, Ferreira E, Rocha H. Hyperargininemia presenting as persistent neonatal jaundice and hepatic cirrhosis. J Pediatr Gastroenterol Nutr 1997; 24: 218-21.
6. Deignan JL, Marescau B, Livesay JC, et al. Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia. Mol Genet Metab 2008; 93: 172-8.
7. Deignan JL, De Deyn PP, Cederbaum SD, et al. Guanidino compound levels in blood, cerebrospinal fluid, and post-mortem brain material of patients with argininemia. Mol Genet Metab 2010; 100(Suppl. 1): S31-6.
8. Marescau B, De Deyn PP, Lowenthal A, et al. Guanidino compound analysis as a complementary diagnostic parameter for hyperargininemia: follow-up of guanidino compound levels during therapy. Pediatr Res 1990; 27: 297-303.
9. Wiechert P, Marescau B, De Deyn PP, Lowenthal A. Hyperargininemia, epilepsy and the metabolism of guanidino compounds. Padiatr Grenzgeb 1989; 28: 101-6.
10. Mizutani N, Hayakawa C, Ohya Y, Watanabe K, Watanabe Y, Mori A. Guanidino compounds in hyperargininemia. Tohoku J Exp Med 1987; 153: 197-205.
11. Stockler S, Schutz PW, Salomons GS. Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. Subcell Biochem 2007; 46: 149-66.
12. Marescau B, Qureshi IA, De Deyn P, Letarte J, Ryba R, Lowenthal A. Guanidino compounds in plasma, urine and cerebrospinal fluid of hyperargininemic patients during therapy. Clin Chim Acta 1985; 146: 21-7.
13. Wyse AT, Bavaresco CS, Hagen ME, et al. In vitro stimulation of oxidative stress in cerebral cortex of rats by the guanidino compounds accumulating in hyperargininemia. Brain Res 2001; 923: 50-7.
14. De Deyn PP, Marescau B, Macdonald RL. Guanidino compounds that are increased in hyperargininemia inhibit GABA and glycine responses on mouse neurons in cell culture. Epilepsy Res 1991; 8: 134-41.
15. Jain-Ghai S, Nagamani SC, Blaser S, Siriwardena K, Feigenbaum A. Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported? Mol Genet Metab 2011; 104: 107-11.